Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Carbohydrate antigen 125 (CA-125) is an emerging prognostic biomarker for heart failure. We aimed to test the long-term prognostic value of CA-125 in combination with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute decompensated heart failure (ADHF). Methods: This observational study included a total of 413 patients (64.1 ± 15.6 yearold, 214 men) with ADHF. All-cause mortality during the 2-year follow-up was investigated for the prognosis. Results: During the follow-up (mean follow-up, 591 ± 233 days), 109 deaths (26.0%) were recorded. In the multivariable analysis model, CA-125 was an independent factor associated with all-cause mortality (log CA-125: hazard ratio, 1.23; 95% confidence interval, 1.02 to 1.48; p = 0.030) together with age, sex, New York Heart Association class, β-blocker, and NT-proBNP. The Kaplan-Meier survival analysis demonstrated that the group with both low marker levels showed the best 2-year survival (87.9%) followed by the group with low NT-proBNP and high CA-125 (76.1%), high NT-proBNP and low CA-125 (64.7%) and high NT-proBNP and high CA-125 levels (54.3%) (p < 0.001). Addition of CA-125 in combination with NT-proBNP and established risk factors further increased the predictive power for mortality in patients with ADHF. Conclusions: CA-125 was an independent factor associated with all-cause mortality in patients with ADHF. Combination of CA-125 with NT-proBNP significantly improved the prediction of mortality in patients with ADHF.
Abstract
Background/Aims: Carbohydrate antigen 125 (CA-125) is an emerging prognostic biomarker for heart failure. We aimed to test the long-term prognostic value of CA-125 in combination with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute decompensated heart failure (ADHF). Methods: This observational study included a total of 413 patients (64.1 ± 15.6 yearold, 214 men) with ADHF. All-cause mortality during the 2-year follow-up was investigated for the prognosis. Results: During the follow-up (mean follow-up, 591 ± 233 days), 109 deaths (26.0%) were recorded. In the multivariable analysis model, CA-125 was an independent factor associated with all-cause mortality (log CA-125: hazard ratio, 1.23; 95% confidence interval, 1.02 to 1.48; p = 0.030) together with age, sex, New York Heart Association class, β-blocker, and NT-proBNP. The Kaplan-Meier survival analysis demonstrated that the group with both low marker levels showed the best 2-year survival (87.9%) followed by the group with low NT-proBNP and high CA-125 (76.1%), high NT-proBNP and low CA-125 (64.7%) and high NT-proBNP and high CA-125 levels (54.3%) (p < 0.001). Addition of CA-125 in combination with NT-proBNP and established risk factors further increased the predictive power for mortality in patients with ADHF. Conclusions: CA-125 was an independent factor associated with all-cause mortality in patients with ADHF. Combination of CA-125 with NT-proBNP significantly improved the prediction of mortality in patients with ADHF.
참고문헌 (31)
- Whitcomb BW, "Circulating levels of cytokines during pregnancy : thrombopoietin is elevated in miscarriage", Fertil Steril, 89, pp.1795~1802 (2008)
- Maisel AS, "Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure", N Engl J Med, 347, pp.161~167 (2002)
- Anand IS, "Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial(Val-HeFT)", Circulation, 107, pp.1278~1283 (2003)
- Baumgarten G, "Cytokines as emerging targets in the treatment of heart failure", Trends Cardiovasc Med, 10, pp.216~223 (2000)
- Tsutamoto T, "Interleukin-6spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure", J Am Coll Cardiol, 31, pp.391~398 (1998)
- Vizzardi E, "Carbohydrate antigen 125 : a new biomarker in heart failure", Cardiol Rev, 21, pp.23~26 (2013)
- Crespo Valades E, "Elevated CA 125in chronic liver disease with ascites", Gastroenterol Hepatol, 27, pp.558~ (2004)
- Fernandez J, "CA125 serum levels in tubercolosis patients", Int J Biol Markers, 10, pp.180~181 (1995)
- Lindgren J, "The ovarian cancer associated antigen CA 125 in patients with pleural effusions", Eur J Cancer Clin Oncol, 24, pp.737~739 (1988)
- Zuckerman E, "Cancer antigen 125 : a sensitive marker of ascites in patients with liver cirrhosis", Am J Gastroenterol, 94, pp.1613~1618 (1999)
- Mezger J, "Elevated serum CA 125levels in patients with benign ascitic or pleural effusions", Tumour Biol, 9, pp.47~52 (1988)
- Kouris NT, "The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters", Eur J Heart Fail, 7, pp.199~203 (2005)
- D'Aloia A, "Serum levels of carbohydrate antigen 125 in patients with chronic heart failure : relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and shortterm prognosis", J Am Coll Cardiol, 41, pp.1805~1811 (2003)
- Varol E, "Tumour marker levels in patients with chronic heart failure", Eur J Heart Fail, 7, pp.840~843 (2005)
- Yilmaz MB, "Plasma CA-125 level is related to both sides of the heart : a retrospective analysis", Int J Cardiol, 149, pp.80~82 (2011)
- Kouris NT, "Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure", Hellenic J Cardiol, 47, pp.269~274 (2006)
- Mansour IN, "Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure", Congest Heart Fail, 16, pp.15~20 (2010)
- Kantar M, "Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity", Pediatr Hematol Oncol, 25, pp.723~733 (2008)
- Koglin J, "Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure", J Am Coll Cardiol, 38, pp.1934~1941 (2001)
- Nunez J, "Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure", Eur Heart J, 31, pp.1752~1763 (2010)
- Pencina MJ, "Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers", Stat Med, 30, pp.11~21 (2011)
- Pencina MJ, "Evaluating the added predictive ability of a new marker : from area under the ROC curve to reclassification and beyond", Stat Med, 27, pp.157~172 (2008)
- Hung CL, "Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women", Am J Cardiol, 110, pp.993~1000 (2012)
- Karaca O, "Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy : a useful biomarker for prognosis and functional mitral regurgitation", Congest Heart Fail, 18, pp.144~150 (2012)
- De Gennaro L, "Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation", Eur J Clin Invest, 42, pp.371~375 (2012)
- Antonini-Canterin F, "Heart failure in patients with aortic stenosis : clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement", Int J Cardiol, 128, pp.406~412 (2008)
- Huang F, "New mechanism of elevated CA125 in heart failure : the mechanical stress and inflammatory stimuli initiate CA125synthesis", Med Hypotheses, 79, pp.381~383 (2012)
- Ordu S, "Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels : compared in heart-failure prognostication", Tex Heart Inst J, 39, pp.30~35 (2012)
- Bhalla V, "B-type natriuretic peptide:the level and the drug. Partners in the diagnosis of congestive heart failure", Congest Heart Fail, 10(1 Suppl 1), pp.3~27 (2004)
- Atisha D, "A prospective study in search of an optimal B-natriuretic peptide level screen patients for cardiac dysfunction", Am Heart J, 148, pp.518~523 (2004)
- Huang B, "Effect of B-type natriuretic peptide level on long-term outcome in patients with end-stage heart failure", Am J Cardiol, 118, pp.383~388 (2016)